September 15, 2024

NEJM at ESMO — Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

New England Journal of Medicine, Ahead of Print.

September 12, 2024

Bladder-Preserving Trimodality Treatment for Recurrent High-Grade T1 Bladder Cancer – The ASCO Post

September 12, 2024

Improving the Bladder Cancer Survivorship Experience for Women – Consult QD

September 11, 2024

Improving bladder cancer treatment – Queen’s University

September 10, 2024

Neoadjuvant gemcitabine–cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial – Nature.com